| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2013-10-14 | Argenta (Galapagos subsidiary – UK Belgium) Genentech, a member of the Roche Group (Switzerland - USA) | R&D |
undisclosed | Services contract | ||
| 2013-10-11 | AstraZeneca (UK) Janssen Pharmaceuticals K.K. (Japan) | abiraterone acetate (Zytiga®) | prostate cancer | co-promotion |
Cancer - Oncology | Co-promotion agreement |
| 2013-10-11 | ImmunoGen (USA) Novartis (Switzerland) | antibody-drug conjugate (ADC) technology | licensing |
Cancer - Oncology | Licensing agreement | |
| 2013-10-10 | Evotec (Germany) Harvard University (USA - MA) | novel enteroendocrine mechanisms, pathways and signals regulating key metabolic processes that have disease-modifying potential in diabetic patients | diabetes | R&D |
Metabolic diseases | R&D agreement |
| 2013-10-10 | MRC Technology (UK) Boston University (USA - MA) | anti-IL-16 antibody | inflammatory diseases, Ischaemic Reperfusion Injury (IRI) | development |
Inflammatory diseases - Cardiovascular diseases | Development agreement |
| 2013-10-10 | Genepep (France) BCN Peptides (Spain) | collaboration |
Collaboration agreement | |||
| 2013-10-09 | Active Biotech (Sweden) Ipsen (France) | Tasquinimod TASQ | prostate cancer | co-development |
Cancer - Oncology | Milestone |
| 2013-10-09 | RWTH Aachen University (Germany) Bayer Technology Services (Germany) | Joint Research Center on Computational Biomedicine | R&D |
R&D agreement | ||
| 2013-10-08 | Horizon Discovery (UK) Blueprint Medicines (UK) | R&D |
Cancer - Oncology | R&D agreement | ||
| 2013-10-08 | Janssen Pharmaceutical - J&J (USA) GSK (UK) | GSK2336805 (GSK805) | chronic hepatitis C | acquisition |
Infectious diseases | Product acquisition |
| 2013-10-07 | Evolva (Switzerland) Serodus (Norway) | EV-077 | diabetic nephropathy | development |
Metabolic diseases | Development agreement |
| 2013-10-07 | Debiopharm (Switzerland) Experimental Therapeutics Centre (Singapore) | oral small molecules targeting new class of epigenetic modulators | R&D |
Cancer - Oncology | R&D agreement | |
| 2013-10-07 | Isis Pharmaceuticals (USA - CA) GSK (UK) | ISIS-GSK3Rx | undisclosed infectious disease | R&D |
R&D agreement | |
| 2013-10-07 | Immutep (France) Eddingpharm (China) | ImmuFact® IMP321 | first-line metastatic breast cancer, other first-line metastatic indications | development |
Cancer - Oncology | Development agreement |
| 2013-10-07 | Kiadis Pharma (The Netherlands) German Red Cross Blood Donor Service Baden-Wuerttemberg-Hessen (GRCBDS) (Germany) | pharmaceutical development and GMP manufacturing services for ATIR™ | development |
Technology - Services | Services contract | |
| 2013-10-07 | Melinta Therapeutics (USA - CT) | nomination | Infectious diseases | Nomination | ||
| 2013-10-03 | DCPrime (The Netherlands) Janssen Pharmaceuticals - J&J (USA) | DCOne™ technology for the development of a dendritic cell-based vaccine | R&D |
Technology - Services | R&D agreement | |
| 2013-10-03 | MRC Technology (UK) Renishaw Diagnostics (UK) | novel clinical diagnostic tests | development |
Diagnostic - Infectious diseases | Development agreement | |
| 2013-10-03 | Imaxio (France) Vitamfero (France) | IMX313 | collaboration |
Infectious diseases | Collaboration agreement | |
| 2013-10-02 | Valneva (France) International AIDS Vaccine Initiative (IAVI) | EB66® cell line | HIV-Aids | licensing |
Infectious diseases | Licensing agreement |
